trial

Antipsychotic Augmentation With L-Dopa

NCTId NCT01636037
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 13 (actual)
Sponsored by Centre for Addiction and Mental Health
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
13 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-09
Primary completion
2015-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
levodopa/carbidopa (generic version of Sinemet)

Sponsors

Centre for Addiction and Mental HealthLead Sponsor

Investigators

1
Gary Remington, MD PhD FRCPCPrincipal Investigator

Sites

1 total
Toronto, Canada

Linked catalysts

1
Antipsychotic Augmentation With L-Dopa — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE2
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
levodopa/carbidopa (generic version of Sinemet)
drug
lead_sponsor
Centre for Addiction and Mental Health
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Gary Remington, MD PhD FRCPC
person